A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
Status:
Completed
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
The primary purpose of this proof-of-concept clinical study was to evaluate the efficacy and
safety of the study drug, ACH-0144471 (also known as danicopan and ALXN2040), in participants
with C3G who also had significant proteinuria attributable to C3G.